Drilldown: Medicines

4-FA (1) · 5-APB (1) · 5-MAPB (1) · 6-APB (1) · 6-APDB (1) · Apixaban (1) · Butylone (1) · Ephylone (1) · Ethylone (1) · MDA (1) · MDAI (1) · MDEA (1) · MDMA (1) · Mephedrone (1) · Methylone (1) · PMA (1) · PMMA (1) · Rivaroxaban (1)

None (16) · Eliquis (1) · Xarelto (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

MAO inhibitor; monoamine releasing agent (1) · MAO inhibitor; serotonin releasing agent (1) · Monoamine releasing agent (3) · Monoamine releasing agent; 5-HT2A agonist (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Serotonin releasing agent (2) · Serotonin releasing agent; 5-HT2A agonist (3) · Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · '"`UNIQ--vote-000001F6-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-000001F7-QINU`"'. (1) · '"`UNIQ--vote-0000050D-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-0000050E-QINU`"'. (1)

None (16) · '"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"' (1) · '"`UNIQ--vote-0000050F-QINU`"', '"`UNIQ--vote-00000510-QINU`"', '"`UNIQ--vote-00000511-QINU`"', '"`UNIQ--vote-00000512-QINU`"' (1)

None (16) · NVAF: 20 mg PO once daily with the evening meal (15 mg if CrCl 15-50); acute VTE: 15 mg BID for 21 days, then 20 mg daily; CAD/PAD: 2.5 mg BID with aspirin (1) · NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID (1)

None (16) · 2.5 mg, 5 mg tablets (1) · 2.5, 10, 15, 20 mg tablets (1)

None (16) · 10 mg BID for the first 7 days of acute VTE; otherwise 5 mg BID (1) · 30 mg/d (acute VTE first 21 days as 15 mg BID); otherwise 20 mg/d (1)

None (16) · Oral (2)

None (16) · Peak anticoagulant effect 2-4 hours (1) · Peak anticoagulant effect 3-4 hours (1)

None (16) · 12 hours (1) · 24 hours (1)

None (16) · 5-9 hours (elderly: 11-13 hours)'"`UNIQ--ref-00000513-QINU`"' (1) · ~12 hours'"`UNIQ--ref-000001FB-QINU`"' (1)

None (16) · ~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' (1) · ~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses'"`UNIQ--ref-00000514-QINU`"' (1)

None (17) · Avoid in pregnancy; switch to LMWH. Crosses placenta; warfarin-class concerns about fetal hemorrhage and teratogenicity make heparins the preferred class.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (16) · [[USLegal:Prescription only|Rx-only]] in US (2)